Cipla's erlotinib to stay on Indian market but court upholds specific Roche patent
This article was originally published in Scrip
Executive Summary
An Indian court has upheld a specific Roche patent concerning its anticancer, Tarceva (erlotinib), in the country, but deemed that Cipla's cut-price generic version does not infringe the concerned patent.